These stromal cells can create a physical barrier to drug delivery and release pro-survival factors—such as interleukin-6 and stromal-derived factor-1—that modulate tumor cell plasticity and sustain a proangiogenic milieu counteracting VEGF-targeted inhibition [11,29]. The gene discussed is IL6; the disease is neoplasm.